Evidence map›Paper›PMID 37202625›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2023

Testing the Effects of Magnetic Hyperthermia in 2D Cell Culture.

Gary Hannon, Adriele Prina-Mello

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 82% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Gary HannonLaboratory of Biological Characterization of Advanced Materials (LBCAM), Trinity Translational Medicine Institute, Trinity College Dublin, Dublin, Ireland. hannonga@tcd.ie.
Adriele Prina-MelloLaboratory of Biological Characterization of Advanced Materials (LBCAM), Trinity Translational Medicine Institute, Trinity College Dublin, Dublin, Ireland.
Advanced Materials and BioEngineering Research · IESt. James's Hospital · IE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Magnetic hyperthermia is an innovative thermal therapy for the treatment of solid malignancies. This treatment approach utilizes magnetic nanoparticles that are stimulated by alternating magnetic fields to induce temperature elevations in tumor tissue, resulting in cell death. Magnetic hyperthermia is clinically approved for treating glioblastoma in Europe and is undergoing clinical evaluation for prostate cancer in the United States. Numerous studies have also demonstrated efficacy in other cancers, however, and its potential utility extends far beyond its current clinical indications. Despite this great promise, assessing the initial efficacy of magnetic hyperthermia in vitro is a complicated endeavor, with multiple hurdles worth considering, such as accurate thermal monitoring, accounting for nanoparticle interference, and a myriad of treatment controls that make robust experimental planning essential to evaluate treatment outcome. Presented here is an optimized magnetic hyperthermia treatment protocol to test the primary mechanism of cell death in vitro. This protocol can be applied to any cell line and ensures accurate temperature measurements, minimal nanoparticle interference, and controls for multiple factors that can influence experimental outcome.

Indexed as

GlioblastomaHyperthermia, InducedMagnetite NanoparticlesCell Culture TechniquesCell DeathCell Line, TumorHumansMagnetic FieldsMaleMagnetite NanoparticlesApoptosisCancerCell cultureCell deathHeatHyperthermiaIron oxide nanoparticlesMagnetic hyperthermiaMagnetic nanoparticlesNecrosis

Identifiers

PMID37202625
OpenAlexW4377077899

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.